

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following best describes the approximate reduction in the risk of death at 2 years for patients receiving tucatinib, trastuzumab and capecitabine versus control on the HER2CLIMB trial?
 - 10%
 - 30%
 - 50%
 - Greater than 60%
- Which of the following statements best describes Phase III clinical trial observations of trastuzumab deruxtecan compared to ado-trastuzumab emtansine (T-DM1) for patients with HER2-positive breast cancer and brain metastases?
 - T-DXd has comparable intracranial activity to T-DM1
 - T-DXd has better intracranial activity than T-DM1
 - T-DM1 has better intracranial activity than T-DXd
- Which of the following potentially fatal adverse events is associated with trastuzumab deruxtecan?
 - Interstitial lung disease
 - Cytokine release syndrome
 - Hemorrhage
 - Ventricular fibrillation
- Trastuzumab deruxtecan is currently under Phase III evaluation for which of the following settings?
 - With or without pertuzumab as first-line treatment for HER2-positive metastatic breast cancer
 - For patients with advanced HER2-positive breast cancer with or without brain metastases
 - For patients with advanced HER2-low breast cancer
 - All of the above
- What was the approximate median CNS progression-free survival observed for patients with advanced HER2-positive breast cancer treated with tucatinib, trastuzumab and capecitabine on the HER2CLIMB trial?
 - 4 months
 - 9.5 months
 - 14 months
 - 18.5 months